Predictors and timing for the development of symptomatic gastroesophageal reflux disease after successful Helicobactor pylori eradication therapy

References

• Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment Pharmacol Ther. 1999;13(2):155–162.
   PubMed Web of Science ®Google Scholar
• Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(3):435–445.
   PubMed Web of Science ®Google Scholar
• Hamada H, Haruma K, Mihara M, et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther. 2000;14(6):729–735.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44(6):518–534.
   PubMed Web of Science ®Google Scholar
• Osawa H, Kita H, Ohnishi H, et al. Helicobacter pylori eradication induces marked increase in H+/K+-adenosine triphosphatase expression without altering parietal cell number in human gastric mucosa. Gut. 2006;55(2):152–157.
   PubMed Web of Science ®Google Scholar
• Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22(5):e12415.
   PubMed Web of Science ®Google Scholar
• Yamamori K, Fujiwara Y, Shiba M, et al. Prevalence of symptomatic gastro-oesophageal reflux disease in Japanese patients with peptic ulcer disease after eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2004;20(Suppl 1):107–111.
   PubMed Web of Science ®Google Scholar
• Murai T, Miwa H, Ohkura R, et al. The incidence of reflux oesophagitis after cure of Helicobacter pylori in a Japanese population. Aliment Pharmacol Ther. 2000;14 (Suppl 1):161–165.
   PubMed Web of Science ®Google Scholar
• Mermelstein J, Chait Mermelstein A, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol. 2018;11:119–134.
   PubMed Web of Science ®Google Scholar
• Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(03):87–97.
   Google Scholar
• Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172–180.
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Kim HC, Pandolfino JE. Approaches to the diagnosis and grading of hiatal hernia. Best Pract Res Clin Gastroenterol. 2008;22(4):601–616.
   PubMed Web of Science ®Google Scholar
• Kakuta E, Yamashita N, Katsube T, et al. Abdominal symptom-related QOL in individuals visiting an outpatient clinic and those attending an annual health check. Intern Med. 2011;50(15):1517–1522.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain CA, European Helicobacter and Microbiota Study Group and Consensus panel, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30.
   PubMed Web of Science ®Google Scholar
• Miwa H, Kusano M, Arisawa T, Japanese Society of Gastroenterology, et al. Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol. 2015;50(2):125–139.
   PubMed Web of Science ®Google Scholar
• Labenz J, Blum AL, Bayerdörffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112(5):1442–1447.
   PubMed Web of Science ®Google Scholar
• Gillen D, Wirz AA, McColl KE. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology. 2004;126(4):980–988.
   PubMed Web of Science ®Google Scholar
• Furuta T, Baba S, Takashima M, et al. H+/K+-adenosine triphosphatase mRNA in gastric fundic gland mucosa in patients infected with Helicobacter pylori. Scand J Gastroenterol. 1999;34(4):384–390.
   PubMed Web of Science ®Google Scholar
• Furuta T, Baba S, Takashima M, et al. Effect of Helicobacter pylori infection on gastric juice pH. Scand J Gastroenterol. 1998;33(4):357–363.
   PubMed Web of Science ®Google Scholar
• Osawa H, Kita H, Ohnishi H, et al. Histamine-2 receptor expression in gastric mucosa before and after Helicobacter pylori cure. Aliment Pharmacol Ther. 2005;21(Suppl 2):92–98.
   PubMed Web of Science ®Google Scholar
• Osawa H, Nakazato M, Date Y, et al. Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab. 2005;90(1):10–16.
   PubMed Web of Science ®Google Scholar
• Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51(8):751–767.
   PubMed Web of Science ®Google Scholar
• Dennish GW, Castell DO. Inhibitory effect of smoking on the lower esophageal sphincter. N Engl J Med. 1971;284(20):1136–1137.
   PubMed Web of Science ®Google Scholar
• Zhang M, Hou ZK, Huang ZB, et al. Dietary and lifestyle factors related to gastroesophageal reflux disease: a systematic review. Ther Clin Risk Manag. 2021;17:305–323.
   PubMed Web of Science ®Google Scholar
• Kohata Y, Fujiwara Y, Watanabe T, et al. Long-term benefits of smoking cessation on gastroesophageal reflux disease and health-related quality of life. PLoS One. 2016;11(2):e0147860.
   PubMed Web of Science ®Google Scholar
• Trudgill NJ, Smith LF, Kershaw J, et al. Impact of smoking cessation on salivary function in healthy volunteers. Scand J Gastroenterol. 1998;33(6):568–571.
   PubMed Web of Science ®Google Scholar
• Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 2017;95(2):156–161.
   PubMed Web of Science ®Google Scholar
• Shinozaki S, Osawa H, Hayashi Y, et al. Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep. 2021;14(3):32.
   PubMed Web of Science ®Google Scholar